Thalia Therapeutics acquires Sanmirna

LONDON: Thalia Therapeutics plc announced Wednesday it has agreed to acquire Sanmirna Therapeutics Inc., a move that catapults the biotechnology firm into the clinical stage with a novel RNA therapy for Acute Myeloid Leukaemia. The acquisition, which is conditional upon shareholder approval, is valued…